Market revenue in 2023 | USD 807.9 million |
Market revenue in 2030 | USD 4,117.5 million |
Growth rate | 26.2% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.17% in 2023. Horizon Databook has segmented the Europe cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Europe has a robust pharmaceutical sector with numerous drug discoveries, development, and manufacturing companies. The growing number of pharmaceutical activities is expected to improve the demand for CDMO services.
Moreover, the rising trend of outsourcing services to European countries is expected to contribute to the increasing demand for cell & gene therapy CDMO in this region. Moreover, the growing prevalence of rare diseases, the presence of well-established pharmaceutical companies, rising demand for new drugs, and the expansion of new facilities are some of the major factors expected to propel regional growth. Similarly, the trend of drug discovery, along with emerging R&D activities, is changing market scenarios at a rapid rate.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe cell and gene therapy cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Europe cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account